TEMENOS
9.6.2022 13:32:12 CEST | Business Wire | Press release
Temenos (SIX: TEMN) has been listed as the only ‘Global Power Seller’ in Forrester’s prestigious Global Banking Platform Deals Survey 2022 , the results of which are presented in the report, ‘Identify The Winners In A Consolidating Banking Platform Market To Make Informed Transformation Decisions’. As stated in the Forrester report, Temenos landed more new global banking deals than any other surveyed provider in 2021.
Temenos will present its open platform for composable banking at Money2020, 7-9 June, in Amsterdam .
Temenos was also named the only ‘Top Global Player’ in the survey, based on combined deals, representing a vendor’s ability to enhance its market position and create value for its existing customers. Temenos also maintained its placement as the only ‘Top Global Cross-Seller’ in Forrester’s newest category, introduced last year, which focuses on extended business. According to the Forrester report, ‘extended business deals represent a vendor’s ability to keep creating value for existing customers.’
The Forrester report reconfirmed Temenos’ status as a ‘Top Global Player’ for the 10th consecutive year. This ranking recognizes platforms with over 150 combined deals (new names and extended deals with existing customers) in more than five regions. With 195 deals signed with new and existing customers, Temenos maintained its position. Temenos also retains its position as a Global Power Seller’, the highest status in the vendor pyramid for new deals. With 93 new business deals in 2021, more than double the number of deals of the next surveyed vendor. This marks the 16th consecutive year that Temenos has received recognition from Forrester.
Max Chuard, Chief Executive Officer, Temenos, said: “We are delighted to continue to be recognized in the Forrester Deal Survey. Temenos is the only vendor recognized as a Global Power Seller, a Top Global Player and a Top Global Cross-Seller in the 2022 Deal Survey. Today, banking is happening everywhere, outside of banking channels through embedded financial services. It’s a massive change and a new revenue stream worth $3.6trn by 2030. Banks and non-incumbents need the right platform for agility, scale, and innovation to succeed in this new world. It’s why Temenos is evolving into an open platform for composable banking. A platform where services for retail, corporate and wealth banking can be built and consumed by everyone, including established banks, challengers, and fintechs.”
The report, authored by Jost Hoppermann, Vice President and Principal Analyst, Forrester, states : “Despite all of the banking industry’s efforts to modernize its application landscapes and improve its digital readiness, legacy software still causes major business challenges. While the transformation pace has increased, it has not yet reached all functional areas. […] Forward-looking incumbents have started moving toward lean cores but need time to bring their rich functionality to the new architecture and allow their installed base to catch up. If these vendors belong to the more successful survey participants, banks can get functionally broad solutions with modern architecture and comparably low vendor risk.”
Temenos was most recently recognized as a leader in ‘The Forrester Wave™: Digital Banking Engagement Platforms, Q3 2021 ’ and ‘The Forrester Wave™: Digital Banking Engagement Hubs, Q3 2021’ .
– Ends –
About Temenos
Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 1.2 billion banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220609005552/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom